Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
Hepatitis B remains a major global health problem despite the availability of a safe and effective vaccine. Segments of the population lack access to or respond poorly to the parenteral vaccine, perpetuating the infection-transmission cycle. A low cost, orally delivered vaccine has the potential to alleviate many of these problems. Here we describe the expression of a bioencapsulated hepatitis B surface antigen (HBsAg) in maize and its immunogenicity, demonstrating for the first time a commercially feasible oral subunit vaccine production system for a major disease. This work surmounts previous barriers to plant-produced vaccines by expressing HBsAg at much higher levels and retaining antigen immunogenicity post-processing: factors which facilitated a robust immune response in mice without the need for an adjuvant. This method provides a practical solution to the delivery of a low-cost, stable oral vaccine.
Hayden, C. A., Streatfield, S. J., Lamphear, B. J., Fake, G. M., Keener, T. K., Walker, J. H., ... Howard, J. A.
citation count
38
complete list of authors
Hayden, Celine A||Streatfield, Stephen J||Lamphear, Barry J||Fake, Gina M||Keener, Todd K||Walker, John H||Clements, John D||Turner, Debra D||Tizard, Ian R||Howard, John A